1. P396 Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension. (16th January 2018) Authors: Hyams, J; O'Brien, C D; Padgett, L; Rosh, J; Turner, D; Veereman, G; Griffiths, A; Heyman, M B; Wahbeh, G; Adedokun, J; Strauss, R; Chan, D; Lynch, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P711 Stool microbiome communities predict remission in pediatric Crohn's disease patients even after start of treatment. (21st January 2022) Authors: Verburgt, C; Dunn, K A; Bielawski, J P; Otley, A R; Heyman, M B; Sunseri, W; Shouval, D; Levine, A; de Meij, T; Hyams, J S; Denson, L A; Kugathasan, S; Benninga, M A; de Jonge, W J; Van Limbergen, J E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗